TRK-100STP low dose

Small molecule

TToray Industries, Inc

TRK-100STP low dose is one of 10 small molecule programs targeting Glomerular Disease. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Glomerular DiseaseActive, not recruiting

Glomerular DiseasePhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Glomerular Disease

#DrugCompanyPhaseTrials

Vanrafia

Novartis

Phase 2

1 2

Filspari

TTravere Therapeutics, Inc.

Phase 2

1 3

Povetacicept

Vertex Pharmaceuticals

Phase 2

1 4

Atacicept

Beraprost

1 6

Medrol

Pfizer

Preclinical

—7

Velcade

SShilpa Grover, MD, MPH

Preclinical

1 8

Rayos

RRoxane Laboratories

Preclinical

—9

Methylprednisolone, Prednisone

Bristol-Myers Squibb

Preclinical

1 10

TRK-100STP low dose

TToray Industries, Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Glomerular Disease1 trial

TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)

Completed·TToray Industries, Inc·Phase 2/3·NCT01090037·892 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TRK-100STP low dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TRK-100STP low dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TRK-100STP low dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Toray Industries, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: TToray Industries, Inc

TRK-100STP low dose

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Glomerular Disease1 trial

References

Drug Info

Quick Facts

Related News